Karl-Erik Andersson, MD

Karl-Erik Andersson, MD, Professor

Dr. Karl-Erik Andersson was born and raised in Sweden. He received his medical degree from the University of Lund in 1968, where he subsequently worked as a lecturer in Clinical Pharmacology. He completed his Ph.D. at the Department of Pharmacology, Lund University, in 1973. In 1975 he obtained a Swedish specialist degree in Internal Medicine and was appointed as Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he had the same position at the University of Aarhus, Denmark. From 1978-2006 he was Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden. He has been visiting professor at the Department of Obstetrics and Gynaecology, University of Toronto (1983-1985) and at the Department of Urology, University of Virginia, Charlottesville, USA (1997-1998). From 1993 to 2000 Dr. Andersson was elected Research Dean of the Medical Faculty at the University of Lund. He is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual and Impotence Research. He also serves on the Editorial Boards of several journals including Urology, European Urology, Neurourology and Urodynamics, International Journal of Impotence Research, and British Journal of Pharmacology. During his career, Dr. Andersson has authored more than 700 articles in peer-reviewed international journals.

SYNOPSIS OF AREA OF INTEREST: Dr. Andersson's research interests include urogenital and cardiovascular pharmacology and physiology, clinical trials and regenerative pharmacology.

DETAILED AREA OF INTEREST: Disturbances in urogenital tract function are common, and often based on malfunction of nerves and smooth muscle. Overactive bladder (OAB) syndrome is one of the most common disorders, and symptoms increase with age. OAB is also common in diabetes and neurological disease. Current drugs for treatment of OAB are limited by insufficient efficacy and side-effects, and new approaches are needed. This implies the search for new targets to pharmacologically control bladder function. Erectile dysfunction (ED) is age-related and is found in 30% of men over 60 years. Although sildenafil is efficacious in the treatment for ED, limitations are noted in patient-categories such as diabetes and cardiovascular disease, where ED also is more prevalent. At the Wake Forest Institute for Regenerative Medicine, the peripheral mechanisms involved in bladder overactivity and ED and afferent neuronal functions involved in the regulation of bladder and erectile functions are studied to improve drug therapies and/or to identify new targets for pharmacological treatment of urinary incontinence. A wide variety of molecular biological techniques, functional in vitro methods, and in vivo models are used. These methods will also be applied to characterize pharmacological and physiological properties of engineered tissues in vitro and in vivo, with the purpose of identifying targets to pharmacologically modify their function.

Quick Reference

Institute for Regenerative Medicine

Phone 336-713-7293
Fax 336-713-7290

Richard H. Dean Biomedical Building
391 Technology Way
Winston-Salem, NC 27101
Find A Doctor Ways to Give
Last Updated: 03-04-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.